<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168044">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909844</url>
  </required_header>
  <id_info>
    <org_study_id>2-54-52014-159</org_study_id>
    <secondary_id>2008-000565-39</secondary_id>
    <nct_id>NCT00909844</nct_id>
  </id_info>
  <brief_title>Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study</brief_title>
  <acronym>DECAPUB</acronym>
  <official_title>Follow-up of the Phase III, Multicentre, Non Comparative, One Single Group, Open Study to Assess the Long-term Efficacy and Tolerability of Pamoate of Triptorelin 11.25 mg in Children With Precocious Puberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the protocol is to assess the efficacy of triptorelin 11.25 mg with respect
      to the proportion of children who maintain a regression or stabilisation of sexual maturity
      until the end of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of children with a stabilization or regression of Tanner pubertal stage at the end of the study, as compared to the stage at study entry (M6 of the phase III study 2-54-52014-143)</measure>
    <time_frame>M12, M24, M36, M48 and final visit (if applicable)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Luteinizing Hormone (LH) response to Gonadotropin-Releasing Hormone (GnRH) tests</measure>
    <time_frame>M12, M24, M36, M48 and final visit (if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of oestradiol in girls or testosterone in boys both measured by radioimmunoassay (RIA)</measure>
    <time_frame>M12, M24, M36, M48 and final visit (if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH) response to GnRH test</measure>
    <time_frame>M12, M24, M36 M48 and final visit (if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI) and BMI Standard Deviation (SD) score for the chronological age variation</measure>
    <time_frame>M12, M24, M36, M48 and final visit (if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Auxological parameters variations (height, growth velocity, weight variation)</measure>
    <time_frame>M12, M24, M36, M48 and final visit (if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone age variation</measure>
    <time_frame>M12, M24, M36, M48 and final visit (if applicable)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of girls with an uterine length &lt; 36 mm</measure>
    <time_frame>M12, M24, M36, M48 and final visit (if applicable)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Precocious Puberty</condition>
  <arm_group>
    <arm_group_label>Triptorelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin (I.N.N.)</intervention_name>
    <description>Decapeptyl® SR 11.25mg</description>
    <arm_group_label>Triptorelin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The child must have completed study 2-54-52014-143

          -  The child must have an effective response to 2 injections of triptorelin 11.25 mg
             according to investigator's evaluation with no significant treatment side effects

        Exclusion Criteria:

          -  The patient has a known hypersensitivity to any of the test materials or related
             compounds

          -  The patient is unable or unwilling to comply fully with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier GATTOLLIAT, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Hôtel Dieu (CHU)</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Flaubert</name>
      <address>
        <city>Le Havre</city>
        <zip>76083</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet II</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Memorial Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Gespe</name>
      <address>
        <city>Tarbes</city>
        <zip>65013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31026</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 29, 2016</lastchanged_date>
  <firstreceived_date>May 28, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
